Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Biocon and Mylan Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S.

Posted On: 2019-12-02 23:52:47


This FDA-approved product, co-developed by Biocon Biologics and Mylan, was unanimously recommended by the FDA Oncologic Drugs Advisory Committee

Mylan to offer Ogivri in both the 420mg and 150mg strengths, increasing access to treatment for thousands of HER2-positive breast and gastric cancer patients

Biocon Ltd. (BSE code: 532523, NSE: BIOCON) and Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin® (trastuzumab). Ogivri is available in a 420mg multi-dose vial and a 150mg single-dose vial in order to provide patient dosing and treatment flexibility.

Ogivri was the first biosimilar trastuzumab approved by the U.S. Food and Drug Administration (FDA) and unanimously recommended by the FDA Oncologic Drugs Advisory Committee (ODAC). Ogivri is approved for all indications of Herceptin including for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma). Trastuzumab and biosimilar trastuzumab products contain a Boxed Warning for cardiomyopathy, infusion reactions, pulmonary toxicity and embryo-fetal toxicity.

Two supplemental Biologics License Applications were recently approved by the FDA, expanding the manufacturing capability for Ogivri, as well as Mylan and Biocon's first U.S. biosimilar, Fulphila®, a biosimilar to Neulasta®. Mylan and Biocon Biologics have sufficient manufacturing capacity to fulfil demand in the U.S. and global markets for both products.

Dr Christiane Hamacher, CEO, Biocon Biologics, said: "The U.S. launch of Ogivri, the biosimilar trastuzumab co-developed by Biocon Biologics and Mylan, marks a significant milestone in our biosimilars journey. It is an important endorsement of our science, development and manufacturing capabilities in the area of monoclonal antibodies. The introduction of both 420mg multi-use vials and 150mg single-use vials of a high quality biosimilar trastuzumab with robust long-term efficacy and safety data will offer greater choice and value to patients, prescribers and payors in the U.S. As a global frontrunner in biosimilars, Biocon Biologics is committed to fulfil unmet patient needs by providing greater affordability for enhanced patient access. We aspire to serve 5 million patients through our biosimilars portfolio and cross a revenue milestone of US$ 1bn by FY22.

"Ogivri is the second biosimilar from our partnered portfolio being commercialized by Mylan in the U.S. Last year, through the launch of Fulphila we helped in expanding patient access to biosimilar Pegfilgrastim," she added.

Mylan President Rajiv Malik commented: "As one of the largest suppliers of oncology medicines in the U.S., we are proud to offer Ogivri, biosimilar trastuzumab, in both the 420mg and 150mg strengths and help increase more affordable access to this important treatment option for breast and gastric cancer patients. With regulatory approval for our biosimilar trastuzumab in more than 80 countries worldwide, we are bringing vast global biosimilars experience to the U.S. and look forward to continuing our work with all stakeholders in the healthcare system to reduce costs, improve access and advance care. With Ogivri, Fulphila and our generic oncology portfolio, Mylan is uniquely positioned to provide a broad range of treatment options for oncology patients."

Malik continued, "Today's launch has been achieved through years of hard work, as a result of our successful collaboration with Biocon. Our early settlement and license with Roche to bring this product to market allows us to launch Ogivri without legal risk."

FDA approval of Ogivri was based on robust data demonstrating that Ogivri is highly similar to Herceptin and no clinically meaningful differences exist between the biosimilar product and Herceptin in terms of safety, purity and potency. Long-term results of the landmark HERITAGE study including overall survival data at 36 months were presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting.

Dr. Hope S. Rugo, professor of medicine at the University of California, San Francisco, and lead author of the HERITAGE study commented: "Trastuzumab-dkst (Ogivri) has many firsts to its credit. It was one of the first biosimilar oncology products to get a unanimous approval vote at an ODAC meeting, and it was the first biosimilar study to be published in the Journal of the American Medical Association. In this context, the HERITAGE study had a unique trial design that not only evaluated objective response rate at week 24 as its primary endpoint but also assessed key endpoints including progression-free survival rate and overall survival at 36 months. The concordant efficacy data across all three endpoints conclusively demonstrated that Ogivri was similar to Herceptin, and patients without progression now continue on Ogivri as maintenance therapy. We are pleased that patients with HER2-positive cancers now have an additional treatment option backed by robust safety and efficacy data, including long-term 36-month data. The worldwide introduction of this agent has already improved access to trastuzumab."

Ogivri is the second biosimilar to be offered by Mylan through the Mylan-Biocon Biologics partnership in the U.S. and the second FDA-approved biosimilar through this collaboration to support cancer patients. A full suite of patient services for Ogivri will be offered through the Mylan Advocate program. Mylan and Biocon launched the world's first biosimilar trastuzumab in India in 2014.

Today, Mylan has one of the largest and most diverse biosimilars portfolios, with 20 biosimilar and insulin analog products in development or on the market.

Shares of BIOCON LTD. was last trading in BSE at Rs.285.95 as compared to the previous close of Rs. 281.65. The total number of shares traded during the day was 399358 in over 6254 trades.

The stock hit an intraday high of Rs. 291.9 and intraday low of 281.95. The net turnover during the day was Rs. 114772369.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Paushak Limited receives approval for expanding production capacity of Phosgene to 14,400 MTPA

Thomas Cook (India) Limited announces results for Q1 FY21

Info Edge India Ltd fixes floor price of QIP as Rs. 3177.18

LIC ups stake in YES Bank to 4.989% through market purchase

Persistent Receives 2020 Workato Partner Award for Innovation

Infosys USA certified as Great Place To Work®

Eris Lifesciences Ltd Board declares Interim Dividend of Rs. 5.50

Thomas Cook India Ltd Q1FY21 consolidated loss at Rs. 94.20 crore

PTC India Financial Services Ltd posts consolidated PAT of Rs. 26.56 crore

Sun Pharma Advanced Research Company Ltd Q1FY21 PAT at Rs. 56.69 crore

MRPL Q1 consolidated loss at Rs. 719.78 crore

ITC's Paperboards Unit at Bhadrachalam conferred with GreenCo Platinum+ rating by CII Green Business Centre for its Environmental Stewardship

NMDC registers record jump in production and sales of iron ore in July 2020

Titan Eyeplus in association with Sankara Nethralaya, Chennai launches Teleconsultation Eye care Services for its customers across the country

JSPL Felicitates its COVID-19 warriors

IndiGo repatriated 212 Indians citizens from Russia

Axis Bank Limited announces opening of QIP, floor price fixed as Rs. 442.19

Narayana Hrudalaya Ltd Q1 FY21 Consolidated operating income at Rs 3,935 mn

Tata Consumer Products Ltd announces results for the quarter ended 30th June 2020

Geojit Announces Appointment of Alice G. Vaidyan to the Board

Maruti Suzuki - Delivering sustainable growth through inclusive approach

ASM Technologies Ltd Board recommends interim dividend of Rs. 2

Digitate Launches ignio™ AI.Assurance to Transform Software Testing and Speed Up Software Release Cycles

Lupin Receives Tentative Approval for Empagliflozin Tablets

Sun Pharma launches FluGuard® (Favipiravir) in India at Rs. 35 per tablet

PI Industries Ltd posts consolidated net profit of Rs. 145.5 crore

Tata Consumer Products Ltd Q1FY20 consolidated PAT surges to Rs. 327.56 crore

Zim Laboratories Ltd Q1 consolidated PAT soars to Rs. 3.28 crore

Uniphos Enterprises Ltd posts Rs. 0.25 crore PAT in Q1FY21

Jenburkt Pharmaceuticals Ltd Q1 PAT at Rs. 1 crore

Gujarat Gas Ltd reports Rs. 59.07 crore consolidated PAT in Q1FY21

Unichem Laboratories Ltd Q1FY21 consolidated net profit at Rs. 2.43 crore

Astral Poly Technik Ltd Q1FY21 consolidated PAT falls

Tamilnadu Petroproducts Ltd Q1 consolidated PAT rises QoQ, drops YoY

Geojit Financial Services Ltd Q1FY21 consolidated net profit jumps to Rs. 23.84 crore

Century Enka Ltd posts Rs. 24.90 crore loss in Q1FY21

Vinyl Chemicals India Ltd reports higher net profit of Rs. 1.16 crore in Q1FY21

Bhansali Engineering Polymers Ltd Q1 consolidated loss at Rs. 1.38 crore

Gujarat Sidhee Cement Ltd reports Rs. 4.98 crore consolidated PAT in Q1

Atishay Ltd posts Q1FY21 net profit of Rs. 0.58 crore

Godrej Consumer Products Ltd Q1FY21 consolidated PAT rises QoQ basis

ASM Technologies Ltd Q1FY21 consolidated PAT at Rs. 3.70 crore

Igarashi Motors India Ltd Q1FY21 loss at Rs. 10.52 crore

HIKAL Ltd Q1FY21 consolidated PAT at Rs. 15 crore

Varun Beverages Ltd Board declares Interim Dividend of Rs. 2.50 for CY2020

Deccan Cements Ltd board to announce Q1 results on Aug 14, 2020

Berger Paints India Ltd board to approve quarterly results on Aug 14, 2020

Marksans Pharma Ltd Q1FY21 Revenue at Rs. 331.3 Cr

Ashok Leyland subsidiary Optare delivers first of 21 battery-electric Metrodecker EV with First York

Ashwini Kumar Tewari Takes Charge as The Managing Director and CEO of SBI Card







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019